Literature DB >> 27285451

Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.

James E Slaven1, Brian S Decker2, Angela D M Kashuba3, Mohamed G Atta4, Christina M Wyatt5, Samir K Gupta6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27285451      PMCID： PMC4981544          DOI： 10.1097/QAI.0000000000001106

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  10 in total

1.  Pharmacokinetics of tenofovir in haemodialysis.

Authors:  Hassane Izzedine; Vincent Launay-Vacher; Vincent Jullien; Guy Aymard; Claudine Duvivier; Gilbert Deray
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

2.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

3.  Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.

Authors:  Brian P Kearney; Kitty Yale; Jaymin Shah; Lijie Zhong; John F Flaherty
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.

Authors:  Trevor Hawkins; Wenoah Veikley; Robert L St Claire; Bill Guyer; Nicole Clark; Brian P Kearney
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

5.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Authors:  Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister
Journal:  Lancet       Date:  2015-04-15       Impact factor: 79.321

6.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

7.  Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

Authors:  F S Rousseau; J O Kahn; M Thompson; D Mildvan; D Shepp; J P Sommadossi; J Delehanty; J N Simpson; L H Wang; J B Quinn; C Wakeford; C van der Horst
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

8.  Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.

Authors:  Elissa J Schwartz; Lynda A Szczech; Michael J Ross; Mary E Klotman; Jonathan A Winston; Paul E Klotman
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

9.  Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.

Authors:  Franck S Rousseau; Charles Wakeford; Herve Mommeja-Marin; Ian Sanne; Cary Moxham; Jeanette Harris; Laura Hulett; Laurene H Wang; Joseph B Quinn; David W Barry
Journal:  J Infect Dis       Date:  2003-10-31       Impact factor: 5.226

10.  Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

Authors:  Richard M W Hoetelmans; Kris Mariën; Martine De Pauw; Andrew Hill; Monika Peeters; Vanitha Sekar; Piet De Doncker; Brian Woodfall; Eric Lefebvre
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335
  10 in total
  4 in total

Review 1.  Clinical Pharmacology in HIV Therapy.

Authors:  Mohamed G Atta; Sophie De Seigneux; Gregory M Lucas
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-29       Impact factor: 8.237

Review 2.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

3.  Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals.

Authors:  Tozammel M D Hoque; Amélie Cattin; Sana-Kay Whyte-Allman; Lee Winchester; Courtney V Fletcher; Jean-Pierre Routy; Petronela Ancuta; Reina Bendayan
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-01       Impact factor: 3.771

Review 4.  Pharmacotherapeutic options for kidney disease in HIV positive patients.

Authors:  Anam Tariq; Hannah Kim; Hashim Abbas; Gregory M Lucas; Mohamed G Atta
Journal:  Expert Opin Pharmacother       Date:  2020-09-21       Impact factor: 4.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.